Product Description
Hoffmann-La Roche is developing Taselisib as a treatment for breast cancer. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02340221)
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location:
Company CEO: Severin Schwan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Breast Cancer
Phase 2: Triple Negative Breast Cancer|Glioma|Prostate Cancer|Esophageal Cancer|Renal Cell Carcinoma|Colorectal Cancer|Breast Cancer|Bladder Cancer|Melanoma|Ovarian Cancer|Hepatocellular Carcinoma|Lymphoma|Squamous Cell Carcinoma|Cervical Cancer|Gastrointestinal Cancer|Endometrial Cancer|Pancreatic Cancer|Head and Neck Cancer|Multiple Myeloma|Brain Death|Neuromyelitis Optica|Vascular Malformations
Phase 1: Lung Cancer|Breast Cancer|Healthy Volunteers|Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02154490 |
Lung-MAP | N/A |
Completed |
Squamous Cell Carcinoma |
2022-04-01 |
2023-06-02 |
Primary Endpoints|Start Date |
|
NCT02390427 |
NCT02390427 | P1 |
Completed |
Breast Cancer |
2022-12-01 |
67% |
2024-10-03 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT01296555 |
PMT4979g | P1 |
Terminated |
Lymphoma, Non-Hodgkin |
2021-06-25 |
50% |
2024-08-01 |
Primary Endpoints |
JapicCTI-142630 |
JapicCTI-142630 | P1 |
Completed |
Breast Cancer |
2017-09-01 |
|||
NCT01862081 |
GO27802 | P1 |
Completed |
Breast Cancer|Lung Cancer |
2017-06-09 |
2019-03-19 |
Treatments |
|
NCT01980953 |
GP28619 | P1 |
Completed |
Healthy Volunteers |
2014-07-01 |
2019-03-20 |
Treatments |
|
NCT01967966 |
GP28755 | P1 |
Completed |
Healthy Volunteers |
2013-12-01 |
2019-03-20 |
Treatments |
|
NCT01814709 |
GP28617 | P1 |
Completed |
Healthy Volunteers |
2013-08-01 |
2019-03-19 |
Treatments |
|
NCT02465060 |
The MATCH Screening Trial | P2 |
Active, not recruiting |
Head and Neck Cancer|Gastrointestinal Cancer|Pancreatic Cancer|Hepatocellular Carcinoma|Lymphoma|Multiple Myeloma|Endometrial Cancer|Glioma|Melanoma|Bladder Cancer|Ovarian Cancer|Prostate Cancer|Renal Cell Carcinoma|Colorectal Cancer|Esophageal Cancer|Breast Cancer|Cervical Cancer |
2026-12-31 |
2025-10-02 |
||
NCT02285179 |
Poseidon | P2 |
Completed |
Breast Cancer |
2022-05-01 |
12% |
2025-02-07 |
Primary Endpoints |
2012-002042-21 |
2012-002042-21 | P2 |
Completed |
Breast Cancer |
2021-06-25 |
50% |
2022-03-13 |
Treatments |
NCT04439175 |
MATCH-Subprotocol I | P2 |
Active, not recruiting |
Multiple Myeloma|Lymphoma |
2020-11-10 |
2024-04-10 |
Primary Endpoints|Study Completion Date|Treatments |
|
2013-003947-51 |
Poseidon | P2 |
Temporarily not available |
Breast Cancer |
2019-10-06 |
2022-03-13 |
Treatments |
|
NCT03290092 |
TOTEM | P2 |
Terminated |
Brain Death|Neuromyelitis Optica|Vascular Malformations |
2019-02-14 |
2019-11-13 |
Patient Enrollment|Primary Completion Date|Study Completion Date |
|
NCT02457910 |
VICC BRE 1374 | P2 |
Terminated |
Triple Negative Breast Cancer |
2018-12-01 |
39% |
2022-08-23 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT02273973 |
LORELEI | P2 |
Completed |
Breast Cancer |
2017-03-13 |
2019-03-20 |
Treatments |
|
2013-000568-28 |
2013-000568-28 | P2 |
Completed |
Breast Cancer |
2017-03-13 |
2022-03-13 |
Treatments |
|
NCT02785913 |
Lung-MAP | P2 |
Completed |
Squamous Cell Carcinoma |
2017-02-01 |
2023-04-20 |
Primary Endpoints|Treatments |
|
NCT02340221 |
SANDPIPER | P3 |
Terminated |
Breast Cancer |
2021-06-29 |
47% |
2022-07-13 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
2014-003185-25 |
2014-003185-25 | P3 |
Completed |
Breast Cancer |
2018-08-18 |
47% |
2025-05-06 |
Treatments|Trial Status |
CTR20160894 |
CTR20160894 | P3 |
Completed |
Breast Cancer |
None |
2025-04-29 |
Patient Enrollment|Start Date |